Omniscient Secures $27.2 Million Series D to Accelerate Commercialization of AI-Enabled Brain Technology
Summary
Omniscient announced it has secured $27.2 million in an oversubscribed Series D funding round co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital will accelerate commercial expansion of the company's FDA-cleared Quicktome platform for connectomic brain mapping and development of new clinical applications in BCI, stroke, and movement disorders. The funding follows the establishment of CPT code 1039T, which creates a reimbursement pathway for connectomic analysis.
Why it matters
This funding validates the commercial viability of AI-driven connectomics as a standard of care in neurosurgery and beyond. By creating patient-specific maps of functional brain regions and neural pathways, Omniscient's platform addresses a critical unmet need for precision brain medicine and positions the company to play an enabling role across multiple high-growth neurotechnology markets including BCI surgical planning.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial